Pathophysiology of Parkinson's disease

Biomedicine and Pharmacotherapy

Volumn 53, Issue 3, 1999, Pages 117-121

  Bonnet, A M ^a   Houeto, J L ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Parkinson's disease; Pathophysiology

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; GLUTAMIC ACID; NEUROPEPTIDE; NORADRENALIN; SEROTONIN;

APOPTOSIS; BASAL GANGLION; CELL DEATH; DOPAMINERGIC NERVE CELL; GENETIC PREDISPOSITION; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0033117212     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80076-6     Document Type: Article

References (48)

1. 1 Langston JW. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 1996 ; 47 : S153-60.
2. 2 Michel PP, Murer G. Neurotoxines et maladie de Parkinson, Les cahiers de Neurologie. 12th International Symposium on Parkinson's disease; 1997 March 23-26. Paris: Interligne;: 1997.
3. 3 Michel PP, Dandapani BK, Sanchez-Ramos JR, Efange S, Pressman BC, Hefti F. Toxic effects of potential environmental neurotoxins related to MPP+ on cultured dopaminergic neurons. J Pharmacol Exp Therap 1989 ; 248 : 842-50.
4. 4 Youdim MB, Riederer P Understanding Parkinson's disease. Sci Am 1997 ; 276 : 52-9.
5. 5 Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G. Familial Parkinson's disease: a clinical and genetic analysis. Can J Neuro Sci 1995 ; 22 : 272-9.
6. 6 Marsden CD. Parkinson's disease in twins. J Neurol Neurosurg and Psychiat 1987 ; 50 : 105-6.
7. 7 Piccini P, Morrish PK, Turjanski N, Sawle GV, Burn DJ, Weeks RA, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 1997 ; 41 : 222-9.
8. 8 Golbe LI, Di Lorio G, Sanges G, Lazzarini AM, La Salas, Bonativa V, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996 ; 40 : 767-75.
9. 9 Polymeropoulos MH, Higgings JJ, Golbe LI, Johnson WG, Iole SE, Di lorio G, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-23. Science 1996 ; 274 : 1197.
10. 10 Vaughan JR, Farrer MJ, Wszolek ZK, and the consortium on genetic susceptibility in Parkinson's disease. Sequencing of the α-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. Hum Mol Gen 1998, in press.
11. 11 Scott WK, Stajich JM, Yamaoka LH, et al. Genetic complexity and Parkinson's disease. Science 1997 ; 277 : 387.
12. 12 Yamamu Y, Sobue I, Ando K, Iida M, Yanagi T, Kono C. Paralysis agitans of early onset with marked diurnal fluctuations of symptoms. Neurology 1973 ; 23 : 239-44.
13. 13 Ishikawa A, Tsuji S. Clinicat analysis of 17 patients in Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996 ; 47 : 160-6.
14. 14 Matsumine H, Saito M, Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa-Hattori Y, et al. Am J Hum Genet 1997 ; 60 : 588-96.
15. 15 Chatuverdi S, Ostbye T, Stoessl AJ, Merskey H, Hachinski V. Environmental exposures in elderly Canadians with Parkinson's disease. Can J Neurol Sci 1995 ; 22 : 232-4.
16. 16 Mayeux R, Tang MX, Marder K, Cote LJ, Stern. Smoking and Parkinson's disease. Mov Disord 1994 ; 9 : 207-12.
17. 17 Marin P, Maus M, Desagher S, Glowinski J, Prémont J. Nicotine protects cultured striatal neurons against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuro-Report 1994 ; 5 : 1980.
18. 18 Le Novère N, Zoli M, Changeux JP. Neuronal nicotinic receptor alpha 6 sub-unit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neuroscien. 1996 ; 8 : 2428-39.
19. 19 German DC, Manaye KK, White CL, Woodward DJ, McIntire DD, Smith WK, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992 ; 32 : 667-76.
20. 20 Van Praag HM, De Haan S. Central serotonin metabolism and frequency of depression. Psychiatr Res 1979 ; 1 : 219-24.
21. 21 Melamed E, Zoldan J, Friedberg G, Goldberg-Stern H. Hallucinosis in Parkinson's disease due to central serotoninergic hyperactivity? Mov Disord 1993 ; 8 : 406.
22. 22 Greenamyre JT, OBrienCF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neur 1991 ; 48 : 977-81.
23. 23 Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with Parkinson's disease. N Engl J Med 1988 ; 318 : 876-80.
24. 24 Haber SN, Watson SJ. The comparative distribution of enkephalin, dynorphin and substance P in the human globus pallidus and basal ganglia forebrain. Neurology 1985 ; 14 : 1001-24.
25. 25 Whitehouse JP, Hedreen JC, White CL, Price D. Basal forebrain neurons in the dementia of Parkinson's disease. Ann Neurol 1983 ; 13 : 243-8.
26. 26 Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 1962 ; 87 : 802-7.
27. 27 Hirsch EC, Graybiel AM, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988 ; 334 ; 345-8.
28. 28 Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 1989 ; 86 : 1398-400.
29. 29 Graham DG, Tiffany SM, Bell WR. Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydoparnine and related compounds towards C-1300 neuroblastoma cells, in vitro. Mol Pharmacol 1978 ; 14 ; 644-53.
30. 30 Jellinger K, Paulu W, Grundke-Iqbal I, Riederer P, Youdim MBH. Brain iron and ferritin in Parkinson's disease and Alzheimer's disease. J Neural transm 1990 ; 2 : 327-40.
31. 31 Zhang P, Darnier P, Hirsch EC, Agid Y, Ceballos-Picot I, Sinet PM, et al. Preferential expression of superoxide dismutase messenger RNA in melanized neurons in human mesencephalon with reference to Parkinson's disease. Neuroscience 1993 ; 55 : 167-75.
32. 32 Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993 ; 52 : 1-6.
33. 33 Shapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease. A critical appraisal. Mov Disord 1994 ; 9 : 125-38.
34. 34 Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, et al. Apoptosis and autophagy in nigral neurons of patients with PD. Histo Histopathol. In press 1997.
35. 35 Bareti RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptosic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998 ; 2 ; 221-7.
36. 36 Ziv I, Melamed E, Nardi N, Luria D, Achiron A, Offen D, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994 ; 170 : 136-40.
37. 37 Kolesnick R, Golbe DU. The sphingornyelin pathway in turner necrosis factor and interleukin-1 signaling. Cell 1994 ; 77 : 325-8.
38. 38 Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors In Parkinson's disease. Neurosci Lett 1994 ; 172 : 151-4.
39. 39 Ricard D, Hunot S, Brugg B, Michel PP, Ruberg M, Faucheux B, et al. Nuclear transcription of NFkB may play a role in the death of dopaminergic neurons in Parkinson's disease. Mov Disord 1997 ; 12 : S1-S8.
40. 40 Albin RL, Young AB, Penney JP. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989 ; 12 : 366-75.
41. 41 Alexander GE, Delong MR. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-71.
42. 42 Gerfen CR, Engber TR, Mahan LC, Susel Z, Chase TN, Monsma FJ, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-32.
43. 43 Parent A, Cicchetti F. The current model of the basal ganglia under scrutiny. Mov Dis 1998; 2: 199-202.
44. 44 Damier P. Lésions, neurochimiques et mécanismes de la mort neuronale. Revue: Maladie de Parkinson. Méd Thor 1997; 3: 182-6.
45. 45 Fearnley JM, Lees AJ. Aging and Parkinson's disease substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
46. 46 Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson Disease's. Brain 1994; 117: 877-97.
47. 47 Lang AE, Lozano AM. Parkinson Disease's (part 11). N Engl J Med 1998; 339: 1130-43.
48. 48 Obeso JA, Rodriguez MC, DeLong MR. The basal ganglia pathophysiology, a critical review. In: Obeso JA, DeLong MR, Ohye C, Marsden CD, eds. The Basal Ganglia and New Surgical Approaches for Parkinson Disease's. Philadelphia: Lippincott-Raven Publishers; 1997. p. 3-18.